Tenofovir versus entecavir in treatment of chronic hepatitis B virus with severe acute exacerbation

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 6, 2015, Pages 3168-3173

  Hung, Chao Hung ^a   Hu, Tsung Hui ^a   Lu, Sheng Nan ^a   Lee, Chuan Mo ^a   Chen, Chih Hung ^a   Kee, Kwong Ming ^a   Wang, Jing Houng ^a   Tsai, Ming Chao ^a   Kuo, Yuan Hung ^a   Chang, Kuo Chin ^a   Chiu, Yi Chun ^a   Chen, Chien Hung ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; TENOFOVIR; VIRUS DNA; ANTIVIRUS AGENT; GUANINE;

ADULT; AGE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ARTICLE; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BODY MASS; CHRONIC HEPATITIS B; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; END STAGE LIVER DISEASE; FEMALE; GENDER; GLOMERULUS FILTRATION RATE; HEPATIC ENCEPHALOPATHY; HEPATITIS B VIRUS; HEPATORENAL SYNDROME; HUMAN; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROTHROMBIN TIME; SIDE EFFECT; THROMBOCYTE COUNT; TREATMENT OUTCOME; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; HEPATITIS B, CHRONIC; MIDDLE AGED; PATHOLOGY;

ADULT; ANTIVIRAL AGENTS; CREATININE; FEMALE; GUANINE; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; TENOFOVIR; TREATMENT OUTCOME;

EID: 84929650166     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00261-15     Document Type: Article

References (33)

1. Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, Guan R, Lau GK, Locarnini S, Chronic Hepatitis B Guideline Working Party of the Asian-Pacific Association for the Study of the Liver. 2008. Asian- Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2:263-283. http://dx.doi.org/10.1007/s12072-008-9080-3.
2. Lee WM. 1997. Hepatitis B virus infection. N Engl J Med 337:1733-1745. http://dx.doi.org/10.1056/NEJM199712113372406.
3. Lok AS, Lai CL. 1990. Acute exacerbations in Chinese patients with chronic hepatitis B virus (HBV) infection. Incidence, predisposing factors and etiology. J Hepatol 10:29-34.
4. Chien RN, Lin CH, Liaw YF. 2003. The effect of lamivudine therapy in hepatic decompensation during acute exacerbation of chronic hepatitis B. J Hepatol 38:322-327. http://dx.doi.org/10.1016/S0168-8278(02)00419-1.
5. Wong VW, Chan HL. 2009. Severe acute exacerbation of chronic hepatitis B: a unique presentation of a common disease. J Gastroenterol Hepatol 24:1179-1186. http://dx.doi.org/10.1111/j.1440-1746.2009.05924.x.
6. Lok AS, McMahon BJ. 2009. Chronic hepatitis B: update 2009. Hepatology 50:661-662. http://dx.doi.org/10.1002/hep.23190.
7. Liaw YF, Kao JH, Piratvisuth T, Chan HL, Chien RN, Liu CJ, Gane E, Locarnini S, Lim SG, Han KH, Amarapurkar D, Cooksley G, Jafri W, Mohamed R, Hou JL, Chuang WL, Lesmana LA, Sollano JD, Suh DJ, Omata M. 2012. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 6:531-561. http://dx.doi.org/10.1007/s12072-012-9365-4.
8. EASL Clinical Practice Guidelines. 2012. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. European Association for the Study of the Liver. J Hepatol 57:167-185.
9. Jindal A, Kumar M, Sarin SK. 2013. Management of acute hepatitis B and reactivation of hepatitis B. Liver Int 33(Suppl 1):S164-S175. http://dx.doi.org/10.1111/liv.12081.
10. Chan HL, Wong VW, Hui AY, Tsang SW, Chan JL, Chan HY, Wong GL, Sung JJ. 2006. Long-term lamivudine treatment is associated with a good maintained response in severe acute exacerbation of chronic HBeAg-negative hepatitis B. Antivir Ther 11:465-471.
11. Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, Dienstag JL, Heathcote EJ, Little NR, Griffiths DA, Gardner SD, Castiglia M. 2003. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 125:1714-1722. http://dx.doi.org/10.1053/j.gastro.2003.09.033.
12. Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, Wichroski MJ, Xu D, Yang J, Wilber RB, Colonno RJ. 2009. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleosidenaive patients is rare through 5 years of therapy. Hepatology 49:1503-1514. http://dx.doi.org/10.1002/hep.22841.
13. Wong VW, Wong GL, Yiu KK, Chim AM, Chu SH, Chan HY, Sung JJ, Chan HL. 2011. Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B. J Hepatol 54:236-242. http://dx.doi.org/10.1016/j.jhep.2010.06.043.
14. Lange CM, Bojunga J, Hofmann WP, Wunder K, Mihm U, Zeuzem S, Sarrazin C. 2009. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology 50:2001-2006. http://dx.doi.org/10.1002/hep.23346.
15. Hsu YC, Mo LR, Chang CY, Perng DS, Tseng CH, Lo GH, Tai CM, Lin CW, Hsu CC, Hsu CY, Huang SC, Lin JT. 2012. Entecavir versus lamivudine in the treatment of chronic hepatitis B patients with hepatic decompensation. Antivir Ther 17:605-612. http://dx.doi.org/10.3851/IMP2027.
16. Chen T, He Y, Liu X, Yan Z, Wang K, Liu H, Zhang S, Zhao Y. 2012. Nucleoside analogues improve the short-term and long-term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure. Clin Exp Med 12:159-164. http://dx.doi.org/10.1007/s10238-011-0160-7.
17. Chen CH, Lin CL, Hu TH, Hung CH, Tseng PL, Wang JH, Chang JY, Lu SN, Chien RN, Lee CM. 2014. Entecavir vs. lamivudine in chronic hepatitis B patients with severe acute exacerbation and hepatic decompensation. J Hepatol 60:1127-1134. http://dx.doi.org/10.1016/j.jhep.2014.02.013.
18. Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, Manns M, Kotzev I, Tchernev K, Buggisch P, Weilert F, Kurdas OO, Shiffman ML, Trinh H, Washington MK, Sorbel J, Anderson J, Snow-Lampart A, Mondou E, Quinn J, Rousseau F. 2008. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 359:2442-2455. http://dx.doi.org/10.1056/NEJMoa0802878.
19. Wong SN, Lok ASF. 2006. Tenofovir disoproxil fumarate: role in hepatitis B treatment. Hepatology 44:309-313. http://dx.doi.org/10.1002/hep.21307.
20. Garg H, Sarin SK, Kumar M, Garg V, Sharma BC, Kumar A. 2011. Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure. Hepatology 53:774-780. http://dx.doi.org/10.1002/hep.24109.
21. Hung CH, Lu SN, Wang JH, Lee CM, Chen TM, Tung HD, Chen CH, Huang WS, Changchien CS. 2003. Correlation between ultrasonographic and pathologic diagnoses of hepatitis B and C virus-related cirrhosis. J Gastroenterol 38:153-157. http://dx.doi.org/10.1007/s005350300025.
22. Hung CH, Chen CH, Lu SN, Wang JH, Hu TH, Huang CM, Tsai MC, Lee CM. 2012. Precore/core promoter mutations and hepatitis B virus genotype in hepatitis B and C dually infected patients treated with interferon-based therapy. Antiviral Res 93:55-63. http://dx.doi.org/10.1016/j.antiviral.2011.10.018.
23. Shouval D. 2014. The pros and cons of lamivudine vs. entecavir in decompensated or severe acute exacerbation of chronic hepatitis B. J Hepatol 60:1108-1109. http://dx.doi.org/10.1016/j.jhep.2014.03.004.
24. Tillmann HL, Zachou K, Dalekos GN. 2012. Management of severe acute to fulminant hepatitis B: to treat or not to treat or when to treat? Liver Int 32:544-553. http://dx.doi.org/10.1111/j.1478-3231.2011.02682.x.
25. Sun LJ, Yu JW, Zhao YH, Kang P, Li SC. 2010. Influential factors of prognosis in lamivudine treatment for patients with acute-on-chronic hepatitis B liver failure. J Gastroenterol Hepatol 25:583-590. http://dx.doi.org/10.1111/j.1440-1746.2009.06089.x.
26. Ceylan B, Yardimci C, Fincanci M, Eren G, Tozalgan U, Muderrisoglu C, Akkoyunlu Y. 2013. Comparison of tenofovir and entecavir in patients with chronic HBV infection. Eur Rev Med Pharmacol Sci 17:2467-2473.
27. Doʇan ÜB, Kara B, Gümürdülü Y, Soylu A, Akin MS. 2012. Comparison of the efficacy of tenofovir and entecavir for the treatment of nucleos(t)ide-naive patients with chronic hepatitis B. Turk J Gastroenterol 23:247-252.
28. Ke W, Liu L, Zhang C, Ye X, Gao Y, Zhou S, Yang Y. 2014. Comparison of efficacy and safety of tenofovir and entecavir in chronic hepatitis B virus infection: a systematic review and meta-analysis. PLoS One 9:e98865. http://dx.doi.org/10.1371/journal.pone.0098865.
29. Wong GL, Wong VW, Choi PC, Chan AW, Chim AM, Yiu KK, Chan HY, Chan FK, Sung JJ, Chan HL. 2009. Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B. Gut 58:111-117. http://dx.doi.org/10.1136/gut.2008.157735.
30. Jin X, Chen YP, Yang YD, Li YM, Zheng L, Xu CQ. 2012. Association between hepatic steatosis and entecavir treatment failure in Chinese patients with chronic hepatitis B. PLoS One 7:e34198. http://dx.doi.org/10.1371/journal.pone.0034198.
31. Duarte-Rojo A, Heathcote EJ. 2010. Efficacy and safety of tenofovir disoproxil fumarate in patients with chronic hepatitis B. Therap Adv Gastroenterol 3:107-119. http://dx.doi.org/10.1177/1756283X09354562.
32. Heathcote EJ, Gane EJ, de Man RA. 2010. Long-term (4 year) efficacy and safety of tenofovir disoproxil fumarate (TDF) treatment in HBeAg-positive patients with chronic hepatitis B (study 103). Hepatology 52(Suppl 1):Abstract 477.
33. Moore JK, Love E, Craig DG, Hayes PC, Simpson KJ. 2013. Acute kidney injury in acute liver failure: a review. Expert Rev Gastroenterol Hepatol 7:701-712. http://dx.doi.org/10.1586/17474124.2013.837264.